- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 1.1 Second Amended and Restated Articles of Association, As Amended
- 2.3 Description of Securities Registered Under Section 12 of the Exchange Act of 1934, As Amended
- 4.47 Concerted Action Agreement Between Aptorum Therapeutics Limited and Peace Range Limited Dated December 30, 2021 Regarding to Mios Pharmaceuticals Limited
- 4.48 Concerted Action Agreement Between Aptorum Therapeutics Limited and Peace Range Limited Dated December 30, 2021 Regarding to Scipio Life Sciences Limited
- 8.1 List of Subsidiaries
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 15.1 Consent of Marcum Bernstein & Pinchuk LLP
- Download Excel data file
- View Excel data file
Exhibit 13.1
Certifications Pursuant to 18 U.S.C. Section 1350
Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Aptorum Group Limited (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report on Form 20-F for the year ended December 31, 2021 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: April 29, 2022
/s/ Ian Huen | |
Ian Huen | |
Chief Executive Officer (Principal Executive Officer) |
Dated: April 29, 2022
/s/ Sabrina Khan | |
Sabrina Khan | |
Chief Financial Officer (Principal Financial Officer) |